February 03, 2026
As of 1 February, Jesper Verhey MSc, has taken on the role of CEO of OncoInv. This step marks the next phase in the company’s development, building on the progress of recent years and placing responsible clinical implementation and real-world evidence generation at the centre of its work.
Over the past years, OncoInv has established a global presence. OncoSeek® is currently implemented across multiple healthcare contexts and countries, each with its own clinical, organisational and societal characteristics. These experiences reinforce a key insight: early cancer detection is not defined by a test alone, but by how it is thoughtfully embedded within care programmes and pathways.
OncoInv will strengthen and connect existing implementations. Progress depends on close collaboration with healthcare providers, academic partners and local experts to ensure that programmes are designed and implemented in ways that are medically sound ethically responsible and appropriate to their specific context.
In support of this work, OncoInv will be looking to secure funding to strengthen the development of real-world evidence, building on insights from existing implementations and partnerships.
A clear example of this approach is the collaboration with the University of Costa Rica, where OncoInv works alongside local academic and healthcare partners to support the responsible integration of early cancer detection within the Costa Rican healthcare setting. Insights gained through such partnerships contribute to learning across regions and help inform implementation efforts elsewhere.
With Jesper as CEO, OncoInv emphasises leadership that connects experience, listens to partners and actively brings networks together. The focus is on learning across implementations, strengthening programmes and scaling responsibly, guided by the company’s mission: Accelerating accessible early cancer detection.
You can reach out to Jesper via mail or connect on LinkedIn.
